Keros Therapeutics Inc (NASDAQ:KROS)’s traded shares stood at 0.86 million during the last session, with the company’s beta value hitting 1.28. At the close of trading, the stock’s price was $16.42, to imply a decrease of -2.32% or -$0.39 in intraday trading. The KROS share’s 52-week high remains $73.00, putting it -344.58% down since that peak but still an impressive 4.57% since price per share fell to its 52-week low of $15.67. The company has a valuation of $665.13M, with an average of 3.19 million shares in intraday trading volume over the past 10 days and average of 828.61K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Keros Therapeutics Inc (KROS), translating to a mean rating of 1.43. Of 3 analyst(s) looking at the stock, 0 analyst(s) give KROS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.51.
Keros Therapeutics Inc (NASDAQ:KROS) trade information
After registering a -2.32% downside in the last session, Keros Therapeutics Inc (KROS) has traded red over the past five days. The 5-day price performance for the stock is -2.96%, and -71.39% over 30 days. With these gigs, the year-to-date price performance is -58.70%. Short interest in Keros Therapeutics Inc (NASDAQ:KROS) saw shorts transact 2.2 million shares and set a 5.28 days time to cover.
The extremes give us $96 and $107 for target low and target high price respectively. As such, KROS has been trading -551.64% off suggested target high and -484.65% from its likely low.
Keros Therapeutics Inc (KROS) estimates and forecasts
Looking at statistics comparing Keros Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Keros Therapeutics Inc (KROS) shares are -64.07% down over the last 6 months, with its year-to-date growth rate lower than industry average at 8.85% against 16.60%. The rating firms project that company’s revenue will grow 19,656.67% compared to the previous financial year.
Revenue forecast for the current quarter as set by 12 analysts is 34.21M. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 22.23M.Earnings reports from the last fiscal year show that sales brought in 143k and 83k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 23,821.91% before jumping 26,687.14% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -111.11% for the past 5-year period. While 2024 is set for a 0.22% return in earnings, projections for the next 5 years are at 4.80% annually.
KROS Dividends
Keros Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Keros Therapeutics Inc (NASDAQ:KROS)’s Major holders
Keros Therapeutics Inc insiders hold 5.43% of total outstanding shares, with institutional holders owning 100.86% of the shares at 106.66% float percentage. In total, 100.86% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 4.72 million shares (or 16.0279% of shares), all amounting to roughly $215.69 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 2.51 million shares, or about 8.5348% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $114.86 million.
